Application of ofloxacin or derivative thereof in preparation of extracellular vesicle secretion inhibitor
By using ofloxacin or its derivatives to inhibit the secretion of extracellular vesicles, combined with anti-PD-1 monoclonal antibody, the problem of lack of effective inhibition of extracellular vesicles in the prior art has been solved, and a variety of factors have been significantly improved The therapeutic effect of tumors, especially the inhibition of PD-L1+ extracellular vesicles, enhances the effect of immunotherapy.
Patent Information
- Application Number
- CN202411167567.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-23
- Publication Date
- 2024-12-03
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
The prior art lacks effective methods and strategies to inhibit extracellular vesicles secretion, especially the inhibition of specific subtypes of extracellular vesicles, which affects the therapeutic effect of various diseases.
The use of ofloxacin or its derivatives as an inhibitor of extracellular vesicles secretion, and by significantly inhibiting the secretion of total extracellular vesicles and specific subtypes of extracellular vesicles, combined with anti-PD-1 monoclonal antibody for anti-PD-1 Tumor treatment.
Ofloxacin significantly inhibits the secretion of extracellular vesicles of a variety of tumor cells, especially the secretion of PD-L1+ extracellular vesicles, improves the immunotherapy effect of tumors such as malignant melanoma and oral squamous cell carcinoma, and in animal models The content of extracellular vesicles in tumor tissue and circulating blood was significantly reduced.
Smart Images

Figure CN119055657A_ABST
Abstract
Citation Information
Patent Citations
Application of levofloxacin antibiotic in preparation of sensitization drug for anticancer drugs and anticancer drug comprising levofloxacin antibiotic
CN110755438A
Nanoparticles containing quinolone compound, preparation comprising nanoparticles containing quinolone compound and application of nanoparticles containing quinolone compound
CN111374961A
Immune checkpoint inhibitor and application
CN114652814A
